Conducting vaccine clinical trials in sub-Saharan Africa: Operational challenges and lessons learned from the Meningitis Vaccine Project

Vaccine

Volumn 30, Issue 48, 2012, Pages 6859-6863

  Marchetti, Elisa ^a   Mazarin Diop, Véronique ^b   Chaumont, Julie ^a   Martellet, Lionel ^a   Makadi, Marie Françoise ^a   Viviani, Simonetta ^a   Kulkarni, Prasad S ^c   Preziosi, Marie Pierre ^d  

^a PATH   (France)

^b Agence Africaine de Recherche en Santé Humaine   (Senegal)

^c Serum Institute of India Ltd   (India)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Africa; Clinical trial operations; Low resources settings; Meningococcal A conjugate vaccine

Indexed keywords

MENINGOCOCCUS VACCINE;

ARTICLE; DRUG SAFETY; GAMBIA; GHANA; GOOD CLINICAL PRACTICE; HUMAN; IMMUNOGENICITY; MALI; MENINGOCOCCOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENEGAL; VACCINATION;

AFRICA SOUTH OF THE SAHARA; BIOMEDICAL RESEARCH; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84868209163     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.008     Document Type: Article

References (15)

1. Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999, 93:341-353.
2. Lapeyssonnie L. La méningite cérébrospinale en Afrique. Bull World Health Organ 1963, 28(Suppl. 1):3-114.
3. Stephens D.S., Greenwood B., Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369(9580):2196-2210.
4. LaForce F.M., Konde K., Viviani S., Preziosi M.P. The Meningitis Vaccine Project. Vaccine 2007, 25S:A97-A100.
5. http://www.meningvax.org/.
6. LaForce F.M., Ravenscroft N., Djingarey M., Viviani S. Epidemic meningitis due to group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009, 27S:B13-B19.
7. LaForce F.M., Okwo-Bele J.M. Eliminating epidemic group A Meningococcal Meningitis in Africa through a new vaccine. Health Aff 2011, 30(6).
8. Kshirsagar N., Mur N., Thatte U., Gogtay N., Viviani S., Preziosi M.P., et al. Safety, immunogenicity and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007, 26S:A101-A107.
9. Hirve S., Bavdekar A., Pandit A., Juvekar S., Patil M., et al. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a 2 phase II/III double-blind randomized controlled trial. Vaccine 2012, Available online 13 August 2012.
10. Sow S., Okoko B., Diallo A., Viviani S., Borrow R., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364:2293-2304.
11. ICH Harmonised Tripartite Guideline for Good Clinical Practice E6(R1), Current step 4 version dated 10 June 1996.
12. Trotter C.L., Greenwood B. Meningococcal carriage in the African meningitis belt. Lancet Infect Dis 2007, 7(December (12)):797-803.
13. Djingarey M.H., Barry R., Bonkoungou M., Tiendrebeogo S., Sebgo R., Kandolo D., et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience. Vaccine 2012, 30(April (Suppl. 2)):B40-B45. 2012.
14. Maïga D., Akanmori B.D., Chocarro L. Regulatory oversight of clinical trials in Africa: Progress over the past 5 years. Vaccine 2009, 27:7249-7252.
15. Maïga D, Akanmori BD, Chocarro L. Joint reviews and inspections: Strategic forms of collaboration for strengthening the regulatory oversight of vaccine clinical trials in Africa. Vaccine 2010; 28: 571-575.